AEON Biopharma reports positive ABP-450 biosimilarity data, secures $6M PIPE and debt reduction

AEON Biopharma, Inc.

ABP-450 shows 100% amino-acid sequence identity to BOTOX (93-99% coverage across five proteins) and highly similar functional characteristics.
FDA Type 2a meeting scheduled for November 19, 2025 to review analytical package ahead of biosimilar pathway.
$6M PIPE and Daewoong note exchange expected to reduce outstanding debt by over 90% and extend cash runway into Q2 2026.
Cash and equivalents $5.9M as of Sep 30, 2025; combined financing expected to fund operations through Q2 2026.
ABP-450 has global approval in 69 countries, supporting fully scaled manufacturing platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.